Stay updated with breaking news from Nasdaq Repl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group (NASDAQ:REPL – Get Free Report) and Zura Bio (NASDAQ:ZURA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Replimune Group has a […]
Profund Advisors LLC lifted its position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 19.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 31,557 shares of the company’s stock after purchasing an additional 5,045 shares during the quarter. Profund Advisors […]
Loomis Sayles & Co. L P grew its stake in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 8.7% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,290,450 shares of the company’s stock after purchasing an additional 103,223 shares during the quarter. Loomis Sayles & Co. L P’s holdings in Replimune Group […]
Replimune Group (NASDAQ:REPL – Get Free Report) issued its earnings results on Thursday. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.12, Briefing.com reports. Replimune Group Stock Up 0.9 % Shares of REPL traded up $0.07 during trading hours on Friday, hitting $7.79. The stock had […]
Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]